Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
REHOVOT, Israel, Nov. 03, 2016 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Stifel 2016 Healthcare Conference taking place in New York, from November 15 – 16, 2016. Dr. Lieberman’s presentation will take place on Tuesday, November 15 at 9:30am ET.
- Jefferies 2016 London Healthcare Conference taking place from November 16 – 17, 2016. Dr. Lieberman’s presentation will take place on Thursday, November 17 at 11:20am GMT, 6:20am ET.
To access the live webcasts of these presentations, please visit ir.neuroderm.com/. Replays will be available for one month following each presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. The company has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease. The company has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates are ND0612L and ND0612H, which are used for treatment of moderate and advanced Parkinson’s disease patients, respectively, and which are delivered subcutaneously. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1762
